4 recruiting. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Follicular T-Cell Lymphoma: new trials by email Literature Review of Follicular T-Cell Lymphoma trials Research Report on Follicular T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma Soquelitinib, Belinostat, Pralatrexate - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Phase 3 | Recruiting | Corvus Pharmaceuticals, Inc. | 150 | 2024-10-02 | 2026-09-25 |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
| A Registry for People With T-cell Lymphoma Optional Blood Sample and Nail Sample - T-cell Lymphoma, NK-Cell Lymphoma | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2023-07-27 | 2026-05-20 | |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 170 | 2021-10-08 | 2026-10-02 |
Immunoblastic Lymphadenopathy (4) · Lymphoma, T-Cell (4) · Enteropathy-Associated T-Cell Lymphoma (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, T-Cell, Cutaneous (2) · Lymphoma, T-Cell, Peripheral (2) · Mycosis Fungoides (2) · Sezary Syndrome (2) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Prolymphocytic, T-Cell (1) · Lymphoma (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Primary Cutaneous Anaplastic Large Cell (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Subcutaneous panniculitis-like T-cell lymphoma (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphadenopathy (4) · Lymphatic Diseases (4) · Lymphoma, Non-Hodgkin (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma (3) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, Prolymphocytic (1) · Leukemia, T-Cell (1)
10-propargyl-10-deazaaminopterin (1) · Azacitidine (1) · Cyclophosphamide (1) · Doxorubicin (1) · Etoposide (1) · Fenretinide (1) · MAC-ST-001 (1) · Prednisone (1) · Vincristine (1) · belinostat (1) · duvelisib (1)
Alliance for Clinical Trials in Oncology (1) · Corvus Pharmaceuticals, Inc. (1) · Memorial Sloan Kettering Cancer Center (1) · SciTech Development, Inc. (1)
United States (4) · Australia (1) · Canada (1)
Aaron R Mangold, M.D. (1) · Ali Moiin, MD (1) · Ann F Mohrbacher, MD (1) · Auris O Huen, MD, PharmD (1) · Barbara Pro, MD (1) · Brad Haverkos, M.D. (1) · Christiane Querfeld, M.D., Ph.D. (1) · Dipenkumar Modi, MD (1) · Jonathan Moreira, M.D. (1) · Neha Mehta-Shah, MD, MSCI (1) · Oleg E Akilov, MD, PhD (1) · Ryan A Wilcox, MD, PhD (1) · Steven Horwitz, MD (1) · Suresh Mahabhashyam, MD, MPH (1)
U10CA180821 (1)